HCT Shares Holista Colltech Limited
ASX · ASXLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Health and nutrition product expansion offers asymmetric upside from a small revenue base.
Signal breakdown
- ▸Product-development catalyst, but very low liquidity increases risk.
- ▾Below 50-day MA (-14.25%)
- ▾Near 52-week low (0% of range)
Is HCT a buy right now?
Trend: HCT is trading below the 50-day average (-7.50%), RSI 22 — oversold territory, with a 3-month return of -53.75%.
Valuation & quality: fundamentals show net margin -54.6%, revenue growth 3.6% year on year.
Our screen: WATCH (score 0) — Health and nutrition product expansion offers asymmetric upside from a small revenue base.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -14.30% | +16.70% | +14.30% | -25.00% | +33.30% | -37.50% | -20.00% | +0.00% |
Fundamentals
Technical signals
About Holista Colltech Limited
Holista Colltech Limited operates as a research-driven biotech company in Australia, Malaysia, and the United States. The company operates through Supplements, Ovine Collagen, Infection Control Solutions, Food Ingredients, and Corporate segments.
Sector: Consumer Defensive · Industry: Packaged Foods · Australia · Website
Related Consumer Staples picks
Browse: all ASX stocks · Consumer Staples picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.